We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEvolus Inc

Evolus Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
7.42 USD 0.00(0%)
Last update at 2026-11-12T15:38:00Z
VOLUME
45053
Market Cap
522.46M

Momentum Score

…

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.29
Low
7.48
High
52 Week Price Range
3.86
Low
9.31
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Evolus, Inc. markets Jeuveau, a neuromodulator approved for aesthetic use, and operates a commercial platform focused on injectable cosmetics. Long-term growth may be supported by rising demand for minimally invasive procedures, repeat dosing dynamics and potential geographic or label expansion. Investors may find the company's focused brand-building and product lifecycle opportunities attractive.

Key investment risks include concentrated revenue from one marketed product, intense competition from established neuromodulators, execution challenges in scaling the business, regulatory and reimbursement uncertainty, and potential need for additional financing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.42
Dividend Yield
-
Revenue TTM
316.49M
Revenue Per Share
4.86
Gross Profit TTM
210.16M
Debt / Equity
-6.71
ROE
-18729.61%
Net Debt
101.17M
ROCE
-20.77%
Diluted EPS TTM
-0.53

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -50.96M -49.76M -61.51M -74.32M -46.77M
Net income -51.64M -50.42M -61.69M -74.41M -46.81M
Selling general administrative 220.79M 189.33M 157.45M 147.59M 118.36M
Selling and marketing expenses - 8.70M 7.49M - -
Gross profit 192.76M 182.30M 140.53M 92.73M 56.14M
Reconciled depreciation 8.74M 6.02M 5.87M 4.50M 6.31M
Ebit -31.27M -31.02M -47.68M -57.58M -63.62M
Ebitda -22.53M -25.00M -41.81M -59.50M -64.28M
Depreciation and amortization 8.74M 6.02M 5.87M -1.92M -0.67M
Non operating income net other - - - 0.11M -2.36M
Operating income -37.60M -34.41M -49.23M -57.58M -63.62M
Other operating expenses 334.78M 300.69M 251.32M 206.19M 163.29M
Interest expense 19.69M 18.73M 13.83M 9.10M 1.40M
Tax provision 0.68M 0.66M 0.18M 0.10M 0.04M
Interest income 1.93M 3.26M 0.86M 0.12M 0.00M
Net interest income -17.76M -15.47M -12.97M -8.98M -1.40M
Non recurring - - - 2.00M -
Income tax expense 0.68M 0.66M 0.18M 0.10M 0.04M
Total revenue 297.18M 266.27M 202.09M 148.62M 99.67M
Total operating expenses 230.36M 216.72M 189.76M 150.30M 119.75M
Cost of revenue 104.41M 83.97M 61.56M 55.89M 43.53M
Total other income expense net -13.36M -15.35M -12.28M -16.74M 16.85M
Net income from continuing ops -51.64M -50.42M -61.69M -74.41M -46.81M
Net income applicable to common shares - - - -74.41M -46.81M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 225.87M 232.57M 189.00M 177.98M 257.48M
Intangible assets 48.04M 48.75M 47.11M 48.60M 50.62M
Other current assets 7.43M 4.55M 8.06M 5.58M 11.04M
Total liab 248.97M 227.05M 209.69M 159.48M 175.61M
Total stockholder equity -23.11M 5.52M -20.69M 18.50M -422.88M
Other current liab 37.87M 37.55M 31.61M 2.45M 42.37M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -661.04M -609.40M -558.98M -497.29M -422.88M
Other liab - - - 39.87M 44.47M
Good will 21.21M 21.21M 21.21M 21.21M 21.21M
Other assets - - 0.00M 2.81M 32.54M
Cash 53.83M 86.95M 62.84M 53.92M 146.26M
Total current liabilities 75.31M 62.96M 48.29M 46.51M 57.66M
Current deferred revenue 11.55M 14.45M 11.03M 9.01M 7.93M
Net debt 101.17M 43.03M 63.71M 19.28M -71.51M
Short term debt 2.53M 1.72M 1.38M 1.32M 1.26M
Short long term debt total 155.00M 129.98M 126.55M 73.20M 74.74M
Other stockholder equity 638.09M 615.83M 538.72M 516.13M -0.00M
Property plant equipment - - - 2.62M 1.37M
Total current assets 142.92M 151.34M 112.42M 100.80M 178.80M
Net tangible assets - - - -51.31M 10.04M
Short term investments - - - - 146.26M
Net receivables 54.70M 47.68M 30.53M 22.45M 14.66M
Long term debt 146.10M 121.51M 120.36M 71.88M 71.22M
Inventory 26.96M 12.16M 11.00M 18.85M 1.76M
Accounts payable 23.36M 9.24M 4.27M 33.73M 6.09M
Accumulated other comprehensive income -0.16M -0.91M -0.43M -0.34M -
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -497.29M -422.88M
Non currrent assets other 1.20M 0.86M 0.41M 2.81M 2.76M
Non current assets total 82.95M 81.23M 76.58M 77.18M 78.68M
Capital lease obligations 8.90M 8.47M 6.19M 2.54M 3.52M
Long term debt total - - - 71.88M 71.22M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -4.82M -1.63M -2.94M 5.00M
Change to liabilities - - - -4.23M 20.10M
Total cashflows from investing activities -8.45M -4.82M -1.63M -2.94M 4.03M
Net borrowings 24.98M 0.00M 50.00M -0.50M -27.63M
Total cash from financing activities 17.34M 47.41M 44.64M -1.52M 73.05M
Change to operating activities - - - -15.14M -2.21M
Net income -51.64M -50.42M -61.69M -74.41M -46.81M
Change in cash -33.13M 24.11M 8.92M -11.65M 43.69M
Begin period cash flow 86.95M 62.84M 53.92M 65.57M 102.56M
End period cash flow 53.83M 86.95M 62.84M 53.92M 146.26M
Total cash from operating activities -42.27M -18.00M -34.01M -8.77M -33.39M
Issuance of capital stock 0.00M 51.21M 0.00M 0.00M 103.34M
Depreciation 8.74M 6.02M 5.87M 4.50M 6.31M
Other cashflows from investing activities -5.01M -3.35M -1.15M -1.32M -0.58M
Change to inventory -11.12M 3.25M 4.19M -10.69M -2.98M
Change to account receivables -11.51M -19.60M -9.52M -9.39M -5.57M
Sale purchase of stock - - - - 103.12M
Other cashflows from financing activities 16.19M -3.80M -5.36M -2.06M 66.04M
Change to netincome - - - 18.17M 17.44M
Capital expenditures 8.45M 1.47M 1.63M 2.94M 0.97M
Change receivables - - - -9.39M -5.57M
Cash flows other operating - - - -9.17M -22.41M
Cash and cash equivalents changes - - - -92.00M 43.69M
Change in working capital -22.48M -6.60M -5.89M -34.25M -11.54M
Stock based compensation 20.70M 22.25M 16.46M 10.83M 9.58M
Other non cash items 2.39M 10.77M 11.24M 84.58M 9.06M
Free cash flow -50.72M -19.47M -35.63M -11.71M -34.36M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EOLS
Evolus Inc		 -
-%		 7.42 - 16.86 1.65 53.71 2.03 -21.50
MKKGY
Merck KGaA ADR		 -0.74
2.19%		 33.06 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 170.05 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.34
1.66%		 21.18 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Evolus Inc

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

520 Newport Center Drive, Newport Beach, CA, United States, 92660

949 284 4555

https://www.evolus.com

353

Name Title Year Born
Mr. David Moatazedi Pres, CEO & Director 1978
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. Chief Medical Officer and Head of R&D 1962
Ms. Sandra Beaver Chief Financial Officer NA
Mr. David K. Erickson VP of Investor Relations NA
Mr. Jeffrey J. Plumer Gen. Counsel NA
Mr. Kurt Knab VP of Sales NA
Ms. Crystal Muilenburg Chief Marketing Officer 1980
Ms. Jessica Novak Sr. VP of HR NA
Mr. David Moatazedi President, CEO & Director 1978
Ms. Sandra Beaver Chief Financial Officer 1978

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…